How does epigenetic therapy work for Colorectal Cancer

Epigenetic Therapy for Colorectal Cancer: How It Works

I appreciate this question because epigenetic therapy represents an emerging and important approach in colorectal cancer treatment. Let me explain what epigenetics means and how these therapies are being explored.

What Are Epigenetics?

Epigenetics refers to chemical changes that affect how genes are "turned on" or "turned off" without changing the DNA sequence itself. Think of it like dimmer switches on genes rather than on/off switches. These changes can silence tumor-suppressing genes or activate cancer-promoting genes.

Key Epigenetic Mechanisms in Colorectal Cancer

MLH1 Methylation is particularly important in colorectal cancer. According to the NCCN Guidelines for Colon Cancer, some colorectal tumors develop abnormal methylation (a chemical modification) of the MLH1 gene promoter. This silences the MLH1 gene, which normally helps repair DNA mistakes. When MLH1 is turned off this way, it creates a condition called dMMR (deficient mismatch repair) or MSI-H (microsatellite instability-high).

This is clinically significant because:

• These tumors develop thousands of mutations
• The immune system can recognize these mutant proteins as "foreign"
• This creates an opportunity for immunotherapy to work

How Epigenetic Therapy Approaches Work

1. Checkpoint Inhibitor Immunotherapy (Current Standard)

Rather than directly targeting epigenetic changes, current treatment leverages what epigenetic changes reveal about the tumor. According to NCCN Guidelines, patients with dMMR/MSI-H colorectal cancer benefit from PD-1 inhibitors (checkpoint inhibitors like pembrolizumab or nivolumab). These drugs work by:

• Blocking the tumor's ability to hide from the immune system
• Allowing T-cells to recognize and attack cancer cells
• Taking advantage of the high mutation burden created by epigenetic silencing of MLH1

2. POLE/POLD1 Mutations (Emerging Approach)

According to NCCN Guidelines, another epigenetic-related finding is POLE/POLD1 mutations. These genes encode DNA proofreading proteins. When mutated, they cause a "hypermutated phenotype" (very high mutation rate) similar to dMMR/MSI-H tumors.

Research cited in the guidelines shows:

• Patients with pathogenic POLE mutations receiving PD-1/PD-L1 inhibitors had improved outcomes
• Clinical benefit rates: 82.4% (with pathogenic variants) vs. 30.0% (with benign variants)
• Median progression-free survival: 15.1 months vs. 2.2 months

Why This Matters for Treatment

The epigenetic changes (like MLH1 methylation) create a "signature" that tells oncologists:

• This tumor is likely to respond to immunotherapy rather than traditional chemotherapy alone
• The tumor's high mutation burden makes it visible to the immune system

Current Clinical Practice

According to NCCN Guidelines for Colon Cancer, the standard approach is:

1. Test for MMR/MSI status - Universal testing recommended for all colorectal cancer patients
2. If dMMR/MSI-H is found - Checkpoint inhibitor immunotherapy is recommended as first-line treatment for advanced disease
3. If POLE/POLD1 mutations are found - Similar checkpoint inhibitor approach may be beneficial

Important Questions to Ask Your Oncologist

If you have colorectal cancer, consider asking:

1. "Has my tumor been tested for MMR/MSI status and POLE/POLD1 mutations?" - These tests guide treatment decisions
2. "Based on my epigenetic profile, am I a candidate for checkpoint inhibitor immunotherapy?"
3. "What are the expected response rates and side effects of immunotherapy versus chemotherapy for my specific tumor characteristics?"
4. "Are there clinical trials testing newer epigenetic-targeting approaches I might be eligible for?"
5. "How will we monitor my response to treatment, and what does progression look like?"

The Bottom Line

Epigenetic therapy for colorectal cancer doesn't directly "fix" the epigenetic changes. Instead, it exploits what those changes reveal about the tumor—that it has a high mutation burden and is likely visible to the immune system. This understanding has shifted treatment from chemotherapy-only approaches to immunotherapy-based approaches for patients with specific epigenetic profiles.

This is an active area of research, and newer epigenetic-targeting drugs are being studied in clinical trials.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.